Update on gene therapy for hereditary hematological disorders.
The past 3 years have been characterized by a number of impressive advances as well as setbacks in gene therapy for genetic disease. Children with X-linked severe combined immunodeficiency disorder (SCID-X1) have shown almost complete reconstitution of their immune system after receiving retrovirally transduced autologous CD34+ hematopoietic stem cells (HSCs). However, two of 11 treated patients subsequently developed a leukemia-like disease probablydue to the undesired activation of an oncogene. Gene transfer to HSCs resulted in substantial correction of immune function and multi-lineage engraftment in two patients with adenosine deaminase (ADA)-SCID. Several Phase I clinical trials for treatment of hemophilia A and B have been initiated or completed. Partial correction of hemophilia A, albeit transient, has been reported by ex vivo gene transfer to autologous fibroblasts. Intramuscular injection of adeno-associated viral (AAV) vector to patients with severe hemophilia B resulted in evidence of Factor IX gene transfer to skeletal muscle and a separate trial based on hepatic infusion of AAV vector is ongoing. Sustained therapeutic levels of coagulation factor expression have been achieved in preclinical models using retroviral, lentiviral, AAV and high capacity adenoviral vectors. Efficient lentiviral gene transfer to HSC in murine models of beta-thalassemia and sickle cell disease demonstrated sustained phenotypic correction.
Herzog
Roland W
RW
The Children's Hospital of Philadelphia, Abramson Research Center, PA 19104, USA. rwherzog@mail.med.upenn.edu
Arruda
Volder R
VR
D000243:Adenosine Deaminase / Q000172:deficiency / Q000235:genetics; D002986:Clinical Trials as Topic; D018014:Gene Transfer Techniques; D030342:Genetic Diseases, Inborn / Q000235:genetics* / Q000628:therapy*; D015316:Genetic Therapy; D006402:Hematologic Diseases / Q000235:genetics* / Q000628:therapy*; D006453:Hemoglobinopathies / Q000235:genetics / Q000628:therapy; D006467:Hemophilia A / Q000235:genetics / Q000628:therapy; D006801:Humans; D016511:Severe Combined Immunodeficiency / Q000235:genetics / Q000628:therapy
D000243:Adenosine Deaminase